Karl Nadolsky, an obesity-medicine specialist and AACE member, has stated: "Restricting access to GLP-1 receptor agonists through excessive step therapy contradicts the evidence base and delays treatment for a disease with cumulative cardiometabolic harm." The disconnect between this evidence and Kaiser's access barriers represents one of the more visible friction points in obesity pharmacotherapy coverage
This process involves your doctor submitting documentation proving you have a BMI of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related comorbidity (high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, etc.), and documentation of previous weight loss attempts (diet, exercise programs, sometimes previous medications)
The comparison is personal, not absolute
Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitusRationale, design, and baseline characteristics
is an investigator on pharmaceutical trials of semaglutide and CagriSema (NovoNordisk), tirzepatide and retatrutide (Lilly), BI 456906 (Boehringer Ingelheim) and maridebart/cafraglutide (Amgen)
A minimum-standard intake form must capture all of these
